Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124274373 | 12427437 | 3 | F | 20160409 | 20160803 | 20160602 | 20160810 | EXP | JP-AMGEN-JPNSP2016070406 | AMGEN | 6.00 | DEC | F | Y | 54.00000 | KG | 20160810 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124274373 | 12427437 | 1 | PS | G-LASTA | PEGFILGRASTIM | 1 | Subcutaneous | 3.6 MG, UNK | Y | 125031 | 3.6 | MG | SOLUTION FOR INJECTION | ||||||
| 124274373 | 12427437 | 2 | SS | G-LASTA | PEGFILGRASTIM | 1 | Subcutaneous | 3.6 MG, UNK | Y | 125031 | 3.6 | MG | SOLUTION FOR INJECTION | ||||||
| 124274373 | 12427437 | 3 | SS | 5-FU | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | 750 MG, 1X/3WEEKS | 0 | 750 | MG | INJECTION | Q3W | ||||||
| 124274373 | 12427437 | 4 | SS | ENDOXAN | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 750 MG, 1X/3WEEKS | 0 | 750 | MG | INJECTION | Q3W | ||||||
| 124274373 | 12427437 | 5 | SS | EPIRUBICIN HYDROCHLORIDE. | EPIRUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 150 MG, 1X/3WEEKS | 0 | 150 | MG | INJECTION | Q3W | ||||||
| 124274373 | 12427437 | 6 | SS | CELECOX | CELECOXIB | 1 | Oral | 100 MG, BID | 0 | 100 | MG | TABLET | BID | ||||||
| 124274373 | 12427437 | 7 | C | ALOXI | PALONOSETRON HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0.75 MG, 1X/3WEEKS | 0 | .75 | MG | INJECTION | Q3W | ||||||
| 124274373 | 12427437 | 8 | C | DEXART | DEXAMETHASONE SODIUM PHOSPHATE | 1 | Intravenous (not otherwise specified) | 6.6 MG, 1X/3WEEKS | 0 | 6.6 | MG | INJECTION | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124274373 | 12427437 | 1 | Colony stimulating factor prophylaxis |
| 124274373 | 12427437 | 3 | Breast cancer |
| 124274373 | 12427437 | 4 | Breast cancer |
| 124274373 | 12427437 | 5 | Breast cancer |
| 124274373 | 12427437 | 6 | Pain |
| 124274373 | 12427437 | 7 | Prophylaxis |
| 124274373 | 12427437 | 8 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124274373 | 12427437 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124274373 | 12427437 | C-reactive protein increased | |
| 124274373 | 12427437 | Interstitial lung disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124274373 | 12427437 | 1 | 20160305 | 20160305 | 0 | |
| 124274373 | 12427437 | 2 | 20160326 | 20160326 | 0 | |
| 124274373 | 12427437 | 3 | 20160303 | 20160324 | 0 | |
| 124274373 | 12427437 | 4 | 20160303 | 20160324 | 0 | |
| 124274373 | 12427437 | 5 | 20160303 | 20160324 | 0 | |
| 124274373 | 12427437 | 6 | 20160216 | 20160330 | 0 | |
| 124274373 | 12427437 | 7 | 20160303 | 20160324 | 0 | |
| 124274373 | 12427437 | 8 | 20160303 | 20160324 | 0 |